DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting November 20, 2018 • 5:30 AM EST
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results November 14, 2018 • 5:30 AM EST
DelMar Announces Further Validation of the Mechanism of Action of VAL-083 October 10, 2018 • 5:30 AM EDT
DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results September 24, 2018 • 6:00 AM EDT
DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor September 4, 2018 • 5:30 AM EDT
DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM June 26, 2018 • 6:00 AM EDT
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors June 25, 2018 • 6:00 AM EDT
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results May 17, 2018 • 5:30 AM EDT
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM April 17, 2018 • 2:00 PM EDT